Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 8/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 5/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579423 | 0.86 | PTPN1 (0.40) | L3MBTL1PTPN1BCHEACHEANO1 | |
| SCHEMBL6581594 | 0.85 | PTPN1 (0.47) | PTPN1BCHEACHECNR1ANO1 | |
| SCHEMBL6582393 | 0.84 | TP53 (0.41) | L3MBTL1PTPN1CNR1ANO1CNR2 | |
| SCHEMBL6585048 | 0.82 | PTPN1 (0.42) | L3MBTL1PTPN1BCHEACHECNR1 | |
| SCHEMBL6581737 | 0.80 | L3MBTL1 (0.48) | L3MBTL1PTPN1BCHEACHECNR1 | |
| SCHEMBL6584870 | 0.80 | L3MBTL1 (0.48) | L3MBTL1PTPN1BCHEACHECNR1 | |
| SCHEMBL6579756 | 0.77 | PTPN1 (0.49) | PTPN1MAPTSMN1; SMN2 | |
| SCHEMBL6579760 | 0.76 | LMNA (0.39) | L3MBTL1PTPN1BCHEACHECNR1 | |
| SCHEMBL6581762 | 0.75 | PTPN1 (0.51) | L3MBTL1PTPN1ANO1CASP1CASP7 | |
| SCHEMBL6579600 | 0.75 | LMNA (0.42) | L3MBTL1PTPN1BCHEACHECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401822-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2003000671-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | F2R, SERPINE1, SERPINC1 | L3MBTL1 2248/4885PTPN1 1287/4885BCHE 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.